ストックスクリーナーアプリを入手
14.22
1.50%
0.218
Tenax Therapeutics Inc (TENX) 最新ニュース
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
How (TENX) Movements Inform Risk Allocation Models - Stock Traders Daily
Tenax Therapeutics may offer up to $300 million of securities - marketscreener.com
Tenax Therapeutics May Offer Up To $300 Million Of Securities - TradingView
Tenax Therapeutics (NASDAQ: TENX) registers $300M shelf to sell securities - Stock Titan
Tenax wins bullish view at Cantor ahead of pivotal readout - MSN
Tenax Therapeutics: A Binary Bet With Heavy Downside Likely (NASDAQ:TENX) - Seeking Alpha
Tenax Therapeutics (TENX): Cantor Fitzgerald Initiates Coverage with Overweight Rating | TENX Stock News - GuruFocus
Top Cypherpunk Technologies (CYPH) Competitors 2026 - MarketBeat
Published on: 2026-03-17 23:42:59 - baoquankhu1.vn
Tenax stock wins bullish view at Cantor (TENX:NASDAQ) - Seeking Alpha
Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating By Investing.com - Investing.com India
Cantor Fitzgerald Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX) - MarketBeat
Tenax Therapeutics (TENX) Gains Momentum with Phase 3 Trial - GuruFocus
Boothbay Fund Management LLC Purchases Shares of 352,206 Tenax Therapeutics, Inc. $TENX - MarketBeat
This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Guggenheim Raises Price Target for TENX, Maintains Buy Rating | - GuruFocus
Guggenheim Issues Positive Forecast for Tenax Therapeutics (NASDAQ:TENX) Stock Price - MarketBeat
What is Lifesci Capital’s Forecast for TENX Q1 Earnings? - Defense World
What is Lifesci Capital's Forecast for TENX Q1 Earnings? - MarketBeat
Trading Systems Reacting to (TENX) Volatility - Stock Traders Daily
Logos Global Management LP Acquires 615,000 Shares in Tenax Therapeutics Inc - GuruFocus
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Raised to "Strong-Buy" at Lifesci Capital - MarketBeat
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
TENX PE Ratio & Valuation, Is TENX Overvalued - Intellectia AI
William Blair Maintains Outperform on Tenax Therapeutics (TENX) March 2026 - Meyka
Tenax Therapeutics Inc (TENX) Q4 Loss Widens, But Beats Estimates - AlphaStreet
Christopher Giordano Discloses Investment at Tenax Therapeutics with 6.79% Stake - TradingView
Tenax Therapeutics (TENX) CEO reports 6.79% beneficial ownership stake - Stock Titan
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings - AlphaStreet
TENX: LEVEL trial enrollment completed early; global expansion and regulatory preparations advancing - TradingView
Tenax Therapeutics stock gains as trial enrollment complete By Investing.com - Investing.com Canada
Tenax Therapeutics Achieves Phase 3 LEVEL Study Patient Target and Reports 2025 Financial Results; Topline Data Expected Q3 2026 - Minichart
Tenax Therapeutics stock holds at Outperform at Leerink Partners By Investing.com - Investing.com Canada
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Tenax Therapeutics Reports Q4 Loss - National Today
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Tenax Therapeutics, Inc. 2025 Annual Report: Business Strategy, Risk Factors, Clinical Pipeline, and Regulatory Challenges - Minichart
Tenax Therapeutics 2025 Financials: Q4 Loss Beats Analyst EstimatesNews and Statistics - IndexBox
TENAX Therapeutics 10-K: Net loss $52.6M, NOL $56.4M, cash runway into 2027 - TradingView
Tenax Therapeutics (NASDAQ: TENX) outlines Phase 3 PH-HFpEF strategy - Stock Titan
TENX: LEVEL and LEVEL-2 trials advanced, net loss widened, cash reserves support operations through 2027 - TradingView
Tenax Therapeutics (TENX) Completes Patient Enrollment for Phase 3 LEVEL Study - GuruFocus
Tenax Therapeutics (NASDAQ: TENX) ramps Phase 3 TNX-103 trials and widens 2025 loss - Stock Titan
Tenax Therapeutics: Q4 Earnings Snapshot - marketscreener.com
Tenax Therapeutics Q4 net loss widens on higher R&D expenses - TradingView
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
TENX Technical Analysis & ETF Price Forecast - Intellectia AI
Tenax Therapeutics: Fourth Quarter Earnings Overview - Bitget
Logos Global (TENX) discloses 615,000 shares, 9.9% stake in Tenax - Stock Titan
Wall Street Recap: What insider trading reveals about Tenax Therapeutics Inc. stockMarket Rally & Low Risk Entry Point Tips - Naître et grandir
Tenax Therapeutics (NASDAQ:TENX) Shares Cross Above 200 Day Moving AverageHere's What Happened - MarketBeat
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference - GlobeNewswire
How Tenax Therapeutics Inc. (TENX) Affects Rotational Strategy Timing - Stock Traders Daily
Tenax Therapeutics: Some Future Potential (NASDAQ:TENX) - Seeking Alpha
0.99%
3.03%
大文字化:
|
ボリューム (24 時間):